GigaMune Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $400K

  • Investors
  • 9

GigaMune General Information

Description

Developer of in vivo cell therapy technologies intended to enable targeted gene delivery for treating cancer and genetic disorders. The company develops biotechnology platforms focused on delivering gene therapies directly inside the human body using engineered viral vectors, eliminating the need for complex ex vivo cell manufacturing, enabling health specialists to deliver advanced gene therapies more efficiently by enabling direct in-body treatment methods.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 953 Indiana Street
  • San Francisco, CA 94107
  • United States
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Corporate Office
  • 953 Indiana Street
  • San Francisco, CA 94107
  • United States

GigaMune Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GigaMune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Grant 01-Jan-2025 $400K Completed Startup
8. Grant 01-Jan-2024 Completed Startup
7. Grant 01-Jan-2023 Completed Startup
6. Seed Round 01-Dec-2022 Completed Startup
5. Grant 11-Aug-2022 Completed Startup
4. Grant 01-Aug-2021 Completed Startup
3. Angel (individual) 29-Apr-2019 Completed Startup
2. Grant 11-Sep-2018 $300K Completed Startup
1. Grant 01-Jan-2018 $300K Completed Startup
To view GigaMune’s complete valuation and funding history, request access »

GigaMune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view GigaMune’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

GigaMune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of in vivo cell therapy technologies intended to enable targeted gene delivery for treating cancer and genetic
Drug Delivery
San Francisco, CA
10 As of 2026

Rehovot, Israel
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GigaMune Competitors (1)

One of GigaMune’s competitors is Edity Therapeutics, a Venture Capital-Backed company based in Rehovot, Israel.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Edity Therapeutics Venture Capital-Backed Rehovot, Israel
You’re viewing 1 of 1 competitors. Get the full list »

GigaMune Patents

GigaMune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4580664-A1 Engineered enveloped vectors and methods of use thereof Pending 31-Aug-2022
US-12371689-B2 Engineered enveloped vectors and methods of use thereof Active 31-Aug-2022
US-20240067958-A1 Engineered enveloped vectors and methods of use thereof Active 31-Aug-2022
US-20260139247-A1 Engineered enveloped vectors and methods of use thereof Pending 31-Aug-2022
WO-2024050450-A1 Engineered enveloped vectors and methods of use thereof Inactive 31-Aug-2022 C12N15/1082
To view GigaMune’s complete patent history, request access »

GigaMune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GigaMune Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bioverge Venture Capital Minority
Boost VC Accelerator/Incubator Minority
Heroic Ventures Venture Capital Minority
Newsight Tech Angels Angel Group Minority
Reinforced Ventures Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

GigaMune FAQs

  • When was GigaMune founded?

    GigaMune was founded in 2017.

  • Where is GigaMune headquartered?

    GigaMune is headquartered in San Francisco, CA.

  • What is the size of GigaMune?

    GigaMune has 10 total employees.

  • What industry is GigaMune in?

    GigaMune’s primary industry is Drug Delivery.

  • Is GigaMune a private or public company?

    GigaMune is a Private company.

  • What is GigaMune’s current revenue?

    The current revenue for GigaMune is .

  • How much funding has GigaMune raised over time?

    GigaMune has raised $2.71M.

  • Who are GigaMune’s investors?

    Bioverge, Boost VC, Heroic Ventures, Newsight Tech Angels, and Reinforced Ventures are 5 of 9 investors who have invested in GigaMune.

  • Who are GigaMune’s competitors?

    Edity Therapeutics is a competitor of GigaMune.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process